SCHEMBL13668441

SCHEMBL13668441

NC1CCN(C[C@H](O)CO)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.59
ATM Q13315 1/20 0.59
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
USP2 O75604 1/20 0.39
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SLC18A3 Q16572 1/20 0.37
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
KDM4E B2RXH2 1/20 0.36
DRD2 P14416 3/20 0.33
DRD4 P21917 3/20 0.33
DRD3 P35462 3/20 0.33
TSHR P16473 2/20 0.33
CARM1 Q86X55 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21486349 0.82 LMNA (0.41) MAPTATMADRA2AADRA2BADRA2C
Hydrochloric Acid SCHEMBL21460676 0.81 MGAM (0.40) MAPTATMUSP2GNAI3GNAO1
Hydrochloric Acid SCHEMBL21460680 0.81 MGAM (0.40) MAPTATMUSP2GNAI3GNAO1
Hydrochloric Acid SCHEMBL23051574 0.81 MGAM (0.40) MAPTATMUSP2GNAI3GNAO1
SCHEMBL23005103 0.80 GNAI3 (0.39) MAPTATMMEN1KMT2AUSP2
SCHEMBL11250545 0.79 ATM (0.80) MAPTATMADRA2AADRA2BADRA2C
SCHEMBL4251673 0.79 ATM (0.80) MAPTATMADRA2AADRA2BADRA2C
SCHEMBL11727679 0.79
SCHEMBL23155986 0.79 MAPT (0.59) MAPTATMADRA2AADRA2BADRA2C
SCHEMBL23155886 0.79 MAPT (0.59) MAPTATMADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 MAPT 4175/4885ATM 2235/4885ADRA2A 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.